Next Article in Journal
Biscogniauxone, a New Isopyrrolonaphthoquinone Compound from the Fungus Biscogniauxia mediterranea Isolated from Deep-Sea Sediments
Next Article in Special Issue
New Enzyme-Inhibitory Triterpenoid from Marine Macro Brown Alga Padina boergesenii Allender & Kraft
Previous Article in Journal
Chemistry and Bioactivity of Briaranes from the South China Sea Gorgonian Dichotella gemmacea
Previous Article in Special Issue
Different Culture Metabolites of the Red Sea Fungus Fusarium equiseti Optimize the Inhibition of Hepatitis C Virus NS3/4A Protease (HCV PR)
Article Menu

Export Article

Open AccessArticle
Mar. Drugs 2016, 14(11), 203; doi:10.3390/md14110203

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors

1
Group Algae Biotechnology, Department of Applied Biosciences and Process Technology, Anhalt University of Applied Sciences, 06366 Köthen, Germany
2
Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry, 06120 Halle (Saale), Germany
3
Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, 06120 Halle (Saale), Germany
*
Authors to whom correspondence should be addressed.
Academic Editor: Sadanandan E. Velu
Received: 16 September 2016 / Revised: 20 October 2016 / Accepted: 25 October 2016 / Published: 2 November 2016
(This article belongs to the Special Issue Enzyme Inhibitors of Marine Origin)
View Full-Text   |   Download PDF [1067 KB, uploaded 2 November 2016]   |  

Abstract

In recent years, many new enzymes, like glutaminyl cyclase (QC), could be associated with pathophysiological processes and represent targets for many diseases, so that enzyme-inhibiting properties of natural substances are becoming increasingly important. In different studies, the pathophysiology connection of QC to various diseases including Alzheimer’s disease (AD) was described. Algae are known for the ability to synthesize complex and highly-diverse compounds with specific enzyme inhibition properties. Therefore, we screened different algae species for the presence of QC inhibiting metabolites using a new “Reverse Metabolomics” technique including an Activity-correlation Analysis (AcorA), which is based on the correlation of bioactivities to mass spectral data with the aid of mathematic informatics deconvolution. Thus, three QC inhibiting compounds from microalgae belonging to the family of sulfolipids were identified. The compounds showed a QC inhibition of 81% and 76% at concentrations of 0.25 mg/mL and 0.025 mg/mL, respectively. Thus, for the first time, sulfolipids are identified as QC inhibiting compounds and possess substructures with the required pharmacophore qualities. They represent a new lead structure for QC inhibitors. View Full-Text
Keywords: glutaminyl cyclase (QC) inhibitor; microalgae; sulfolipids; AD; reverse metabolomics; Scenedesmus sp.; natural product glutaminyl cyclase (QC) inhibitor; microalgae; sulfolipids; AD; reverse metabolomics; Scenedesmus sp.; natural product
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Hielscher-Michael, S.; Griehl, C.; Buchholz, M.; Demuth, H.-U.; Arnold, N.; Wessjohann, L.A. Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors. Mar. Drugs 2016, 14, 203.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top